Clinical trials: High Risk Prostate Cancer
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Prostate Cancer
High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer
RATIONALE: Highly focused ultrasound energy may be able to kill cancer cells by heating the tumor without affecting the surrounding tissue.
- Trial name
- NCT00030277
- Testing
- high-intensity focused ultrasound ablation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Focus Surgery
Prostate Cancer
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00004124
- Testing
- bicalutamide, goserelin, mitoxantrone hydrochloride
- Where
- 234 sites in United States
- Volunteers
- 983 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy
- Trial name
- PRX32 (NCT03296124)
- Where
- United States
- Sponsor
- University of Florida
Prostate Cancer
Focal Therapy Using HIFU for Localised Prostate Cancer
To evaluate the rate of patients without cancer detected by biopsies performed six months after hemi-ablation with high intensity focused ultrasound (HIFU) (Ablatherm ®).
- Trial name
- NCT02016040
- Testing
- High Intensity Focused Ultrasound
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Jewish General Hospital
Patients With High-risk Prostate Cancer
Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer…
- Trial name
- NCT01800058
- Where
- 3 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Cancer
Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after…
- Trial name
- AdRad (NCT00653848)
- Testing
- docetaxel
- Where
- Norway
- Volunteers
- 378 people
- Sponsor
- Scandinavian Prostate Cancer Group
Prostatic Carcinoma
Imaging of High Grade Prostate Cancer
Management of prostatic carcinoma varies according to stage of disease. Trans-rectal ultrasound guided biopsy is known to underestimate the degree of tumor due to undersampling and random non-targeted technique.
- Trial name
- NCT02177526
- Testing
- Imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer.
- Trial name
- MOB-RT (NCT05313815)
- Testing
- Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Benign Prostate Hyperplasia
Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers
This is a multicenter, cohort study based on medico-administrative data from pathology laboratory registries and drug reimbursement files (CNAM-TS).
- Trial name
- CANARI (NCT02873117)
- Testing
- Prostate biopsy, prostatectomy or prostate resection
- Where
- France
- Volunteers
- 5,154 people
- Sponsor
- Rennes University Hospital
Recovery, Post Prostatectomy
Effects of Exercise Prior to Radical Prostatectomy
This pilot study will explore the metabolic and psychological effects of High-Intensity Interval Training (HIIT) exercise as well as its impact on patient recovery from radical prostatectomy.
- Trial name
- NCT07746414
- Testing
- High-intensity interval training (HIIT) exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Neoplasms, Prostate, Benign Prostatic Hyperplasia
Economic Analyses of the REDUCE Trial
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial.
- Conditions
- Neoplasms, Prostate, Benign Prostatic Hyperplasia, Cancer
- Trial name
- NCT01337258
- Testing
- Dutasteride
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
High Risk Prostate Cancer
Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer
Considering the promising results with hypofractionated in low and intermediate risk prostate cancer, our proposal is to translate this experience to patients with high risk prostate cancer.
- Trial name
- NCT02107287
- Testing
- IMRT Technique
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Sergio Faria
Prostatic Neoplasms
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and…
- Trial name
- LuTectomy (NCT04430192)
- Testing
- 177Lu-PSMA-617
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
High-Risk and Oligometastatic Prostate Cancer
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.
- Trial name
- NCT04997252
- Testing
- Apalutamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhujiang Hospital
Prostate Cancer
Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).
In France, prostate cancer is the most common cancer in men over 50 years of age (nearly 50,000 new cases per year) and is the second most common cause of cancer death in men (approximately 9,000 deaths per year).
- Trial name
- PREOP-PSMA (NCT04745871)
- Testing
- PSMA PET/CT
- Where
- France
- Volunteers
- 112 people
- Sponsor
- University Hospital, Brest
Prostate Cancer
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
The purpose of this study is to determine if treatment with Darolutamide plus androgen deprivation therapy (ADT) before radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized…
- Trial name
- NCT06575257
- Testing
- Darolutamide, Goserelin 3.6 mg
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xijing Hospital
Prostate Cancer, BRCA1 Mutation
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or…
- Conditions
- Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma
- Trial name
- NePtune (NCT05498272)
- Testing
- Olaparib, LHRH agonist
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rana McKay, MD
Prostate Cancer
Training for Men Undergoing Androgen Deprivation Therapy.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
- Trial name
- ADT-train (NCT06449664)
- Testing
- ADT-train
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- The Swedish School of Sport and Health Sciences